Trial Profile
Expanded Access Program for a Multicentre, Open, Non Randomized Study, Evaluating Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA(R)) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs ERY-ASP (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Expanded access
- Acronyms EAP
- Sponsors ERYtech Pharma
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2021 According to a ERYtech Pharma media release, results from this study were presented at 2021 ASH Annual Meeting.
- 13 Dec 2021 Results presented in an ERYtech Pharma media release.